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Abstract: Although pacemaker implantation is considered to be low risk, it is not exempt from
complications and technical failures during the procedure, both in the short and long term, and the
complications that such patients may present remain unknown. The aim has been to analyze the
complication rates associated with permanent pacing and to identify if these differ between patients
with or without previous antithrombotic therapy. We used a prospective, single center, observational
study of 310 adult patients with indications of permanent pacing. They were hospitalized from
1 January to 31 December 2014 and followed up for 6 months after the pacemaker implant. The
participants were distributed into two groups according to the antithrombotic therapy prior to the
implant. The most frequent major complications were pneumothorax (3.87%) and lead dislodgement
(8.39%), while superficial phlebitis (12.90%) and uncomplicated hematomas (22.58%) were presented
as the most recurrent minor complications. Hematomas were the most frequent minor complication
in the antithrombotic therapy cohort, and shoulder pain was reported as the most recurrent minor
complication in the non-exposed group. Finding out about complications in pacemaker implants
enables a complete view of the process, and hence the prioritization of actions aimed at improving
safety and reducing associated risks.
Keywords: pacemaker; artificial; anticoagulant drugs; postoperative complications; patient safety;
prospective studies; outcome assessment
1. Introduction
Cardiac stimulation has become the common treatment of symptomatic bradycardia or high-grade
atrioventricular block. Pacemaker implant rates have increased exponentially in the last few years,
especially in the elderly [1]. The aging of the population, the technological advances of these devices,
and the growing number of clinical indications are the main factors that contribute to the increase
of this rate [2]. It is estimated that each year 1.25 million permanent pacemakers are implanted
worldwide [1]. In 2016, approximately 500,000 permanent pacemakers were implanted in Europe and
there were 37,466 implants in Spain [1]. The 2016 annual report of the Virgen del Rocío University
Hospital indicates that 479 permanent pacemakers were implanted [3].
Although the procedure is considered to be minor surgery, this does not mean that it is exempt
from complications and technical failures in the short and long term [4].
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In this sense, the implant requires special consideration in patients with antithrombotic therapy,
so perioperative management represents a challenge for the care needed by these patients [4].
The aim of our study was to prospectively identify the complication rates of patients after pacemaker
implantation, according to a system of anticoagulant and antithrombotic treatment or without this.
2. Materials and Methods
2.1. Study Design and Participants
We proposed a prospective cohort study [5,6]. The sample was made up of patients with
indications of permanent pacing, hospitalized in any of the Medical–Surgical Units or in the Critical
Care and Emergency Unit of the Virgen del Rocío University Hospital in Seville (Spain) from 1 January
to 31 December of 2014. The patients were followed up for 6 months after the pacemaker implant.
This was done during the first 30 days, by telephone, with cut-off points at 7, 15, and 30 days. In the
case of non-response, they were called again 48 h later to avoid losses during the follow-up procedure.
A review of the clinical history was made after 6 months, exploring the presence of any episode related
to the pacemaker implant documented as a complication.
Considering the aim of the study, all the cases were distributed into two groups depending on
whether they had been prescribed antithrombotic therapy or not before the surgery.
2.2. Inclusion and Exclusion Criteria
In order to include a case in the study, it had to meet three requirements: (a) to be the first
implantation of a permanent pacemaker, (b) the patient had to be older than 18 years old, and
(c) the patient had to sign an informed consent to participate in the study. If patients had generator
replacements, a device removal, or an implantation of defibrillators or resynchronizers, they were
excluded from the sample.
Finally, the inclusion criteria were met by 310 patients.
2.3. Implant Procedure
Implant procedural aspects were defined as elements related to the preparation of the patient
(antibiotic prophylaxis); aspects connected with the technique of the implant (difficulty of central
venous access, use of support with image); data related to perioperative care (surgical wound
compression, arm immobilization); elements related to patient follow-up; and with respect to the work
team, data related to the surgeon’s experience (high >100 implants/year, medium <100 implants/year,
and low <50 implants/year) [7,8]. All patients received compression dressing, local cold on the surgical
wound, and an immobilization of the arm ipsilateral to the pacemaker implant before leaving the
operating room.
2.4. Definition of Exposure
According to the treatment systems followed by the patient before the implantation, in terms
of anticoagulant and antithrombotic treatment, and according to the protocol implemented in the
hospital, the patients were distributed into two strata: (1) patients not treated with antithrombotic
therapy, considered in the analysis as “not exposed” (n = 71; 23%); and (2) patients treated with
anticoagulant and antithrombotic treatment, analyzed as “exposed group” (n = 239; 77%). This last
group was subdivided into 4 different subgroups: (a) patients only with oral anticoagulation (n = 15);
(b) patients with combination therapy consisting of oral anticoagulation/antiplatelet agent/bridging
heparin (n = 103); (c) patients with simple or double antiplatelet therapy (n = 76); and (d) patients only
with heparin (n = 45).
The anticoagulant treatment was Acenocumarol (10 patients) and new oral anticoagulants
(5 patients). Regarding the antithrombotic therapy, the specific drugs were acetylsalicylic acid
(61 patients) and Clopidogrel (9 patients). Finally, 148 patients took low molecular weight heparin.
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2.5. Protocol for Discontinuation of Anticoagulant and Antithrombotic Treatment
The protocol implanted in our Hospital Center varied depending on the level of risk of
thromboembolism. This was evaluated according to the PRETEMED guide [9] since it is one of
the most used in Spain [10]. Therefore, the specific protocols are explained below:
(1) Patients with a mechanical heart valve, atrial fibrillation, or a high risk of thromboembolism are
given bridging heparin (during 48 h after the procedure).
(2) Patients with a mechanical heart valve, atrial fibrillation, or a low risk of thromboembolism stop
anticoagulants therapy 3 days before the procedure, and resume it 24 h after surgery.
(3) In moderate- to high-risk patients who are receiving acetylsalicylic acid, this is maintained around
the time of surgery.
(4) For patients with a coronary stent, antiplatelet therapy is continued perioperatively.
2.6. Definition of Outcomes
Although surgical outcomes were reported as morbidity or mortality rates in the past, more
recent studies have pointed out the appropriateness of considering them more broadly, that is, the
complication rates [11,12]. The major and minor complications were defined (Table 1) based on
previous reports of complications related to such devices [13,14]. On the one hand, major complications
were those that placed the patient at significant risk, such as reoperation, readmissions for management,
or the death of the patient. On the other hand, minor complications were those associated with patient
discomfort, treated on an outpatient basis, or spontaneously resolved, with the intention of our results
being compared with some other studies.
Table 1. Major and minor complications.
Major Complications Minor Complications
Cardiac perforation/cardiac tamponade Cellulitis
Death Local pain
Generator or lead malfunction (lead break, bad connection lead-generator) Shoulder pain
Hematomas with a clinical significance Peripheral nerve injury
Infection Superficial phlebitis
Lead dislodgement Uncomplicated hematomas
Pneumothorax/hemothorax
Pre-erosion or erosion of pocket
Thromboembolic event (transient ischemic attack, Stroke, pulmonary
thromboembolism, thrombosis, deep venous thrombosis)
The data were prospectively collected in a registry designed for this purpose, including the basal
measurements and the outcomes described.
2.7. Statistical Analysis
Standard descriptive statistics were used to summarize the data. Continuous variables were
reported with means and SDs. The qualitative variables were measured and analyzed by proportions.
The differences between groups were analyzed by Chi-square or Student-Fischer-t for qualitative or
quantitative variables, respectively. The relationship between the quantitative and qualitative variables
was carried out by using the Student’s t test for independent samples and the Mann–Whitney U test,
respectively, depending on whether or not the normal distribution was followed.
A level of significance of 5% (p < 0.05) was considered in all the hypothesis verifications. The data
were analyzed with the IBM SPSS version 19 (IBM, Armonk, NY, USA).
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
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approved by the Ethics Committee of Virgen del Rocío University Hospital, Seville, Spain (Project
identification code: 2013PI/152).
3. Results
Main Results
First of all, the main clinical and biological characteristics of the cases included are described in
Table 2. The patients’ mean age was 76.88 ± 9.71 years, and 56.13% of the cases analyzed were male
patients. The diagnosis for the pacemaker implant was mainly due to the alteration of atrioventricular
conduction (49%) and sinus node disease (41.6%). These percentages differed between the two
groups considered. While the most frequent diagnosis in the non-exposed group was the alteration of
atrioventricular conduction (61.97%), in the exposed group the two causes had similar rates (45.19%
and 46.44%).
Table 2. Pre-implant clinical and biological values characteristics.
Total
n = 310 (%)
Non-Exposed
n = 71 (%)
Exposed
n = 239 (%) p-Value
Age (mean ± SD) 76.88 ± 9.71 75.25 ± 12.95 77.36 ± 8.48 NS
Gender
Male 174 (56.13%) 38 (53.52%) 136 (56.90%)
NSFemale 136 (43.87%) 33 (46.48%) 103 (43.10%)
INR (Mean ± SD) 1.10 ± 0.19 1.04 ± 0.09 1.12 ± 0.21 0.000
Diagnosis for
intervention
Sinus node disease 129 (41.6%) 18 (25.35%) 111 (46.44%)
0.006AV conduction
system disease 152 (49%) 44 (61.97%) 108 (45.19%)
Syncope and others 29 (9.4%) 9 (12.68%) 20 (8.37%)
Cardiovascular risk
factors
Hypertension 237 (76.45%) 46 (64.79%) 191 (79.92%) 0.008
Diabetes 109 (35.16%) 15 (21.53%) 94 (39.33%) 0.004
Dyslipidemia 134 (43.23%) 23 (32.39%) 111 (46.44%) 0.035
Obesity (BMI > 28) 186 (60%) 37 (52.11%) 149 (62.34%) NS
Smoking 28 (9.03%) 9 (12.68%) 19 (7.95%) NS
Charlson score [15]
Absence of
comorbidity 202 (65.16%) 59 (83.10%) 143 (59.83%) -
Low and high
comorbidity 108 (34.84%) 12 (16.90%) 96 (40.17%)
HAS-BLED score [16]
Low 96 (30.97%) 48 (67.61%) 48 (20.08%)
Medium 153 (49.35%) 22 (30.99%) 131 (54.81%) <0.000
High 61 (19.68%) 1 (1.41%) 60 (25.10%)
Venous thrombotic
risk [9]
Low 108 (34.84%) 40 (56.34%) 68 (28.45%) 0.000
Medium 60 (19.35%) 16 (22.54%) 44 (18.41%) NS
High 142 (45.81%) 15 (21.13%) 127 (53.14%) 0.000
AV: Atrioventricular, BMI: Body Mass Index, DVT: Deep Venous Thrombosis, HAS-BLED: Hypertension,
Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol
Concomitantly, INR: International Normalized Ratio, n: number of patients, NS: Not Significant,
SD: Standard Deviation.
The order in which cardiovascular risk factors were present in the cases analyzed was
hypertension, obesity, dyslipidemia, diabetes, and, finally, smoking.
As a whole, the biological characteristics of the participants showed a significant baseline
situation of greater fragility in the group with antithrombotic therapy, due to higher comorbidity. The
characteristics of the procedure are shown in Table 3. The implant procedure shows that the central
venous access was the subclavian vein (99%) and the mean duration of the procedure was almost
37 min. Most devices were located subcutaneously and the number of attempts for venous access was
less than three. More dual-chamber pacemakers were implanted in the non-antithrombotic therapy
group (73.24%) vs. the group with antithrombotic therapy (55.23%). In relation to the surgeon’s
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experience, the “non-exposed” group had a higher proportion of intervention by surgeons with much
experience (63.38% vs. 46.03%, respectively).
Table 3. Implant-related characteristics.
Total
n = 310 (%)
Non-Exposed
n = 71 (%)
Exposed
n = 239 (%) p-Value
Cauterizer 17 (5.48%) 4 (5.63%) 13 (5.44%) NS
Incision prior to venous puncture 97 (31.29%) 28 (39.44%) 69 (28.87%) NS
Subclavian vein access 1 308 (100%) 70 (98.59%) 238 (99.58%) NS
Arterial puncture 48 (15.48%) 9 (12.68%) 39 (16.32%) NS
Temporary pacemaker 34 (10.97%) 5 (7.04%) 29 (12.13%) NS
Number of attempts
venous access
<3 229 (73.87%) 54 (76.06%) 175 (73.22%)
NS>3 74 (23.87%) 15 (21.13%) 59 (24.69%)
The opposite side 7 (2.26%) 2 (2.82%) 5 (2.09%)
Device type Pacemaker, dual 184 (59.35%) 52 (73.24%) 132 (55.23%) 0.006Pacemaker, single 126 (40.65%) 19 (26.76%) 107 (44.77%)
Device location
Subcutaneous 299 (96.45%) 68 (95.77%) 231 (96.65%)
NSSubpectoral 11 (3.55%) 3 (4.23%) 8 (3.35%)
Surgeon experience
Low 61 (19.68%) 11 (15.49%) 50 (20.92%) NS
Medium 94 (30.32%) 15 (21.13%) 79 (33.05%) 0.054
High 155 (50%) 45 (63.38%) 110 (46.03%) 0.010
Duration of implantation (Mean ± SD) 36.99 ± 15.47 37.66 ± 15.19 36.79 ± 15.50 NS
1 Two patients are not included in the venous access, this being considered as anecdotal (one is accessed by a
cephalic vein and another by a femoral vein). n: number of patients, NS: Not Significant, OAC/NOAC: Oral
Anticoagulation/New Oral Anticoagulation, SD: Standard Deviation.
According to Table 4, major complications occurred in 17.42% of the cases, and 10 of the patients
experienced more than one major complication. The most frequent major complication in the
first post-implant 24 h was pneumothorax (3.87%) and one patient showed more than one major
complication in the exposed group.
Table 4. Major complications are shown as periprocedural or subsequent up to 6 months of
the follow-up.
Periprocedural (24 h) Totaln = 310
Non-Exposed
n = 71
Exposed
n = 239 p-Value
Pneumothorax 12 (3.87%) 3 (4.23%) 9 (3.76%) NS
Cardiac perforation 1 (0.32%) 0 1 (0.42%) NS
Cardiac tamponade 2 (0.64%) 0 2 (0.84%) NS
Total patients with >1 major complication 1 (0.32%) 0 1 (0.42%) NS
Subsequent Up to 6 Months Totaln = 310
Non-Exposed
n = 71
Exposed
n = 239 p-Value
Lead dislodgement 26 (8.39%) 6 (8.45%) 20 (8.37%) NS
Malfunction 2 (0.64%) 1 (1.41%) 1 (0.42%) NS
Pre-erosion or erosion of pocket 1 (0.32%) 0 1 (0.42%) NS
Infection 5 (1.61%) 0 5 (2.09%) NS
Stroke 4 (1.29%) 0 4 (1.67%) NS
Death 16 (5.16%) 0 16 (6.69%) 0.025
Hematomas with clinical significance 1 (0.32%) 0 1 (0.42%) NS
Total patients with >1 major complication 9 (2.90%) 0 9 (3.76%) 0.097
n: number of patients, NS: Not Significant.
During the 6-month follow-up, the complication rates in accordance with their incidence were
lead dislodgement (8.39%—atrium lead in 14 patients and ventricular lead in 12 patients), followed
by deceased patients (5.16%). All the deaths were located in the exposed group. In this group, nine
patients experienced more than one major complication.
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As a whole, the major complications were 11% more frequent in patients undergoing treatment
with some type of antithrombotic therapy. This could be due to the profile of a higher baseline risk,
age, and comorbidity in the “exposed” group. If deaths were excluded in the comparison, there were
no differences between the two groups.
Minor complications occurred in 37.74% of the cases and there were 21 patients with more than
one minor complication (Table 5).
Table 5. Minor complications are shown as periprocedural or subsequent up to 6 months of
the follow-up.
Periprocedural (24 h) Totaln = 310
Non-Exposed
n = 71
Exposed
n = 239 p-Value
Superficial phlebitis 40 (12.90%) 9 (12.68%) 31 (12.97%) 0.948
Total patients with >1 minor complication 0 0 0
Subsequent Up to 6 Months Totaln = 310
Non-Exposed
n = 71
Exposed
n = 239 p-Value
Uncomplicated hematomas 70 (22.58%) 11 (15.49%) 59 (24.69%) NS
Peripheral nerve injury 5 (1.61%) 1 (1.41%) 4 (1.67%) NS
Pain shoulder 58 (18.71%) 20 (28.17%) 38 (15.90%) 0.019
Cellulitis 1 (0.32%) 0 1 (0.42%) NS
Local pain 6 (1.93%) 1 (1.41%) 5 (2.09%) NS
Total patients with >1 minor complication 21 (6.77%) 6 (8.45%) 15 (6.27%) NS
n: number of patients, NS: Not Significant.
The most frequent minor complications were phlebitis in the first 24 h (40 patients—12.90%)
and hematomas (70 patients—22.58%) during the 6-month follow-up. In this last case, this minor
complication was more frequent in the “exposed” group. The second most recurrent minor
complication was painful shoulder (58 patients—18.71%), with a large percentage in the “non-exposed”
group. It should be noted that the rates of the other minor complications identified were similar in the
two cohorts.
4. Discussion
The present prospective study describes the complications experienced by patients who undergo
permanent pacemaker implant, during the perioperative period and a follow-up of up to 6 months.
The incidence of these complications between patients treated with antithrombotic therapy and those
not exposed to such therapy is compared.
The incidence of complications was higher in patients with antithrombotic therapy (56%)
compared with patients not exposed (52%).
4.1. Major Complications
A cumulative incidence of 70 major complications (22.58%) was observed in 54 patients. Patients
in the exposed group presented more complications than those in the “non-exposed” group (14.08%
vs. 25.10%), respectively. Previous prospective studies reported major complications oscillating
between a global rate of 4.2%, reported by Tobin et al. [7] in 1332 patients, and 12.6%, reported by
Parsonnet et al. [8] in 632 patients. More recent papers [17–20] reported even lower complication rates,
ranging from 4% to 8%.
The most frequent major complication in the follow-up was lead dislodgement (8.39%). In our
series, the rate of lead dislodgement (active fixation) was higher than the previous evidence.
Particularly, the rate of atrium-lead (7.61%) was higher than the rate identified by the literature
(3% [19]–5% [18]).
Prospective studies [17–19] reported a lead dislodgement rate between 2% and 6%, while in a
retrospective study [21] the lead dislodgement rate was 4.8%.
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Information about the causes of lead dislodgement is scarce and it is often difficult to relate lead
displacements to a specific etiology. Among them, it could be highlighted (a) the implant of devices
in a more elderly population with greater co-morbidities, such as left ventricular dysfunction, right
ventricular dilatation, and tricuspid regurgitation [19], and (b) the surgeon’s experience could be
related to dislodgement rates, which suggests that inadequate initial positioning, allowance of lead
slack, and/or anchoring are significant risk factors [19].
A similar problem may occur when the device is not sutured to the underlying pectoralis fascia.
In this scenario, a device lying in the subcutaneous tissue (or in a submuscular space) may gradually
descend through this space and exert traction on the lead.
The risk of this complication is lessened by ensuring a stable position when implanting, leaving a
proper amount of intravascular lead slack so that tension is not exerted at the tip by respiration or arm
motion, adequately anchoring the suture sleeve to the underlying tissue, and limiting the abduction
and elevation of the ipsilateral upper extremity for a short time after implantation.
Pneumothorax was the second most frequent complication (3.87%) and usually appeared in the
first 24 h after the implant. All these patients required drainage and this increased their hospital stay
by two days. There were no significant differences between the cohorts. Its incidence was higher
than the average rate (2%) [13,17,21–23], and the standard proposed by societies such as The National
Cardiovascular Data Registry ICD Registry [23] and the Spanish Society of Intensive and Critical
Medicine, and Coronary Units [24], which suggest a pneumothorax percentage around 0.5% and <2%,
respectively, as a quality indicator. This increase, in our series, could be explained by the technique used
(venous access via subclavian vein puncture) for the implant. Despite this negative impact, this method
is the one preferred by more experienced surgeons. Another explanation of the reason behind the
increase of the rate is the lack of use of safety measures, such as image support or the non-use of veins
and alternative techniques, for example the dissection of the cephalic vein or channeling the axillary
vein to insert the leads. This would reduce the incidence of pneumothorax [23,25–27]. The axillary vein
approach seems to be a favorable technique not only for the prevention of acute complications but also
to reduce lead failure, including lead insulation and lead fracture prevention, having a consequently
better long-term lead survival compared with the classical subclavian approach [26].
The use of a guided image, as recommended by the current venous access guidelines [28], would
be a safe practice that would avoid exposing patients to a greater risk, hence guaranteeing their safety.
An infection due to the implant was experienced in 1.61% of the patients. In this case, infection
was defined as a complication that requires intravenous antibiotics and or system removal/extraction.
All of them were from the exposed cohort. Our series included an infection rate, in line with previous
publications, ranging between 0.4% and 13% [19,20,29]. According to previous evidence [30], this
kind of infection can appear even more than 2 years after the implant, so this rate could reflect an
increase if the follow-up period is extended. A less experienced surgeon could be associated with a
higher probability of patients developing an infection due to the procedure. The greater length of the
procedure, lower skills in surgical techniques, and longer time of prosthesis exposure increase the
likelihood of contamination and more hematomas due to the increased handling of tissues.
The accumulated incidence of deceased patients was 5.16% during the 6-month follow-up, all
located in the with antithrombotic therapy group (0% vs. 6.7%, p = 0.025). These results are similar to
those reported in the literature consulted with follow-ups from 6 months to 1 year [25]. These data
could be explained by the higher comorbidity present in the with antithrombotic therapy cohort and
are concordant with the studies consulted [19,25], which confirm that the comorbidity of patients is a
determinant factor of mortality after pacemaker implant and is related to device implant in a very low
proportion. This considers the opportunity of using predictive scales based on comorbidity that could
help in making complex decisions, such as limiting the therapeutic effort or pacemaker indication.
Cardiac perforation, although relatively uncommon, is a potentially life-threatening
complication [31]. Clinical manifestations are variable, including cardiac tamponade, chest pain,
diaphragmatic stimulation, abdominal pain, and syncope (because of pacing failure). In our study,
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a perforation was observed in one patient, with hemodynamic instability. However, it should be
recognized that the statistics of our research are limited because of the low number of events. Although
active fixation ventricular leads have been considered more prone to perforation [31], in our study,
cardiac perforation used temporary pacemaker leads because they are stiffer [31].
4.2. Minor Complications
An accumulated incidence of 180 minor complications was observed in 117 patients, without
there being significant differences between the two cohorts. Previous research [13,14,18] reported
from 13% [18] to 4% [13,14] of minor complications, although comparisons are complex due to the
differences in the population included in the sample [13,14].
Pocket hematomas without clinical repercussion were the most common complication (22.58%)
in the 6-month follow-up. The rates were higher in the antithrombotic therapy group, although the
differences are not significant. All were conservatively resolved.
The presence of hematomas in our series (22.58%) was higher than that described in previous
studies (2.9% [18], 4% [17], 5% [20]).
These differences could be explained by the inclusion criteria of patients, the periods of suspension
of antithrombotic therapy, the type of implanted devices, the definition of hematoma, or by the study
design. The periods of suspending antithrombotic therapy could be explained by the disorder caused
by discontinuation/re-initiation and the effect of the combination of different drugs on the coagulation
cascade, causing a new bleed that is not controlled during the intraoperative stage. Nevertheless,
if anticoagulation is still active, bleeding can be better controlled, allowing local hemostatic measures
to be taken.
It would be convenient to prepare recommendations about those strategies that are currently
demonstrating higher safety, such as maintaining oral anticoagulation during pacemaker implantation
in patients with a high thrombotic risk [11]. This new strategy would lead us to an optimization of
measures and care for the prevention of hemorrhagic complications (a careful evaluation of the wound
before discharge and informing patients and their relatives about warning signs), without an increase
in the risk of thrombosis [32].
The painful shoulder ipsilateral to the pacemaker implant is a complication usually overlooked
and can be disabling for individuals affected [33]. The accumulated incidence of painful shoulder was
18.71%, significantly more frequent in the cohort of not-exposed patients. It seems possible that these
results are due to the number of days the patients had their arms immobilized, and that this was longer
in the not-exposed group. This finding supports previous research [33–35], which reports 62% of
shoulder pain, 42% with tendinitis 3 months after implantation [34], and 1.1% of frozen shoulder and
33% of shoulder pain [35]. All these data would confirm the relationship between the immobilization
of the arm and the presence of painful shoulder [33]. Such results differ from ours due to the inclusion
of larger devices (defibrillators and resynchronizers), which would explain higher percentages of
this complication.
Therefore, updating and personalizing the information and the recommendations given to
each patient regarding the immobilization of their arms would guarantee the safety of the care
offered. In those people who need more time of immobilization, it would be appropriate to increase
their follow-up, by telephone or by means of an ambulatory face-to face consultation, developing a
subsequent rehabilitation plan that would minimize the effects of this measure.
4.3. Limitations
This is a single center study and, therefore, its outcomes might not necessarily be generalizable
regarding the number of complications, though it would be regarding their causes. The level of
experience of the perioperative nursing team has not been included in the study and therefore its
impact on the final outcome is unknown.
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5. Conclusions
In conclusion, patients who were implanted with a permanent pacemaker in our center in
2014 were mostly men, predominantly elderly, with more cardiovascular risk factors, and a higher
comorbidity index in the group with antithrombotic therapy, which mark them as a more fragile group.
There was a relevant rate of complications related to a permanent pacemaker implant. These
complications occurred in the initial phase after the implant and decreased during the follow-up, the
most frequent ones being pneumothorax, lead dislodgement, peripheral phlebitis, uncomplicated
hematomas, and painful shoulders.
Adverse event variables should be introduced in future pacemaker implant registration reports
to enrich our knowledge concerning the quality of the implant, in accordance with the current safety
culture, as well as to use them to improve the practice.
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